Patrick Cox has lived deep inside transformative technologies for over 25 years. In the 1980s, he worked in software development and manufacturing. By the mid-‘90s, he consulted for Netscape–which handled 90% of all Internet browsing traffic at the time. InfoWorld and USA Today have featured his research, and he’s written for The Wall Street Journal, Los Angeles Times, USA Today and Reason Magazine. Patrick has appeared on Crossfire and Nightline, and been written up in The Baltimore Sun and CNBC Magazine. Now, Patrick edits Breakthrough Technology Alert and Technology Profits Confidential, uncovering transformational technologies that offer exponential gains.
The virtue most required for successful investing is the rarest these days. That virtue, of course, is patience, and it is best illustrated by the model of successful innovation investors, John Templeton. I think, however, that Templeton's circumstances made the virtue of patience far easier to practice. As you know, Templeton borrowed $10,000 in 1939, more than $150,000 in current dollars, and bought every stock trading below $1 on the New York and American stock exchanges. He then went off to war just as Hitler launched his assault on Europe. Templeton had no choice but to ignore his portfolio, which contained mostly innovation startups, until after the war. Then, when the war ended and he was able to get stock market news on a regular basis again, he discovered that he had quadrupled his money.
Today, I want to make sure that you're aware of a near-term significant event for a company in our portfolio. First, I want to talk a bit about the long term. In my youth, I did several years in Hollywood. My mother, thankfully, never found out. I told her I was a contract killer for the Yakuza, or something, to spare her the truth. Initially, my job in Tinseltown was to act as a liaison between real scientists and studios that wanted to bring some accuracy to their portrayals of scientific issues in film and television.
Today, I just want to point out a few events that will, I believe, move the long-term disruptive portion of your portfolio significantly forward. This will be short for several reasons. One, I was late with this month’s issue, which has disrupted my schedule further. I say “further” because of the distractions associated with two pretty complex eye surgeries coming up. It's not just the surgeries themselves. It's all the associated pre- and postop visits with my surgeon. In all, I've got at least nine more appointments in the next month and a half, many up north in Fort Myers.
It's that time of month again, which means that my editorial staff is once again undoubtedly complaining that I'm late with this month's issue. So I had planned to write a short note updating Protext Mobility Inc. and then call it quits. I'll talk about Protext first, but events require that I talk at least a little about remarkable new developments from BioTime.
International Stem Cell Corporation is, of course, the company that developed and patented commercializable human parthenogenetic stem cell (hpSC) science. These stem cells, called either parthenogenic or parthenogenetic stem cells, come from the parthenotes in the female ova or their immature form, oocytes. The word oocyte, incidentally, is pronounced OH-a-site. Parthenotes, as you know, are cells that have shed one half of their DNA in readiness for fertilization. This doesn't mean that these gametes, ova and spermatazoa, have only one strand of the double helix, however. In these cells, both helices of the double helix are the same.
As you know, the technology owned by Applied DNA Sciences Inc. has been chosen by the Defense Logistics Agency (DLA) to protect military supply lines. Applied DNA's plant-based DNA marking inks use a virtually unbreakable genetic encryption strategy to prevent counterfeiting. Moreover, Applied DNA has been named the only technology that will protect suppliers from forfeiting the total cost of any product that is found to contain counterfeit electronics. Currently, the mandate applies to electronics, but there is open discussion of widening the use of this technology to verify the rest of the military supply network. This includes products as diverse as uniforms.
This is just a short note in response to a number of reader inquiries regarding the most recent attempt by short attackers to knock down the Star Scientific stock price. First, however, I should clarify that I'm really not that concerned about short-term stock prices, especially in regard to Star Scientific. The potential of anatabine citrate, the active ingredient in Anatabloc, has been validated by the completed thyroiditis study performed by a number of noted endocrinologists from Johns Hopkins Medical School, chiefly the director of endocrinology and metabolism, Dr. Paul W. Ladenson.
I spent most of last week in Baltimore with the Agora Financial crew. It's always good to brainstorm with the team, and it was fun to watch excitement building over the playoff game which, of course, the Baltimore Ravens won. On the other hand, it's no secret that I don't like travel. I like my office, blocks from the beach with four large-screen monitors, good speakers and glass doors that let me watch my family go about their daily routine. I realize that travel allows certain occasionally useful activities, like shaking someone's hand, but honestly, telephones and the Internet are capable of accomplishing a lot more than most people ever use them for.
Watching this administration pretend that refusing to raise the debt ceiling is our real problem, rather than its spending, is simply surreal. All the major players pushing for more debt, including the president, said exactly the opposite just a few years ago. Then, they were criticizing the prior administration, and rightly so, when the debt was $10 trillion. Now, when it's 60% higher, they are feigning outrage that anybody would take their prior position in support of a balanced budget. The upside to this behavior, however, is that we know certain big things will happen. And whenever you know that something big is going to happen, you can make money.
I hope you've had a pleasant holiday season. As this is the first alert of the new year, I'd like to talk about the two biggest developments of 2012. Coincidentally, both culminated in the last few days, which has me both very tired and very excited. I suspect, by the way, that these two developments will maintain their ranking for years to come. They are BioTime's just-announced acquisition of Geron's massive stem cell patent library and the preliminary data from the Johns Hopkins thyroiditis study using Star Scientific's) nutraceutical anatabine citrate.